Non-COVID revenue grows 38% YoY to Rs 260 Crs.
Metropolis Healthcare has announced its unaudited consolidated financial results for the second quarter (Q2FY22).
Q2FY22 financial highlights
- 8% EBITDA margin (Before CSR & ESOP)
- 60% revenue share of B2C in Focus Cities (Non-COVID)
- 58.4 Crs reported PAT
Ameera Shah, Promoter and Managing Director, Metropolis Healthcare said, “We are pleased to share that we have continued the strong business momentum with recording robust revenue along with profitability during Q2FY22. This strong performance has been on the back of growth in sustainable non-COVID revenue, increased patient visits & tests and increased contribution from specialized tests. With economy now strongly recovering from the pandemic, we expect our non-COVID business to continue grow sustainably. Our recently acquired Hitech Diagnostics will further enable us to scale up our business, improve the B2C revenue contribution and increase our market penetration by catering to the value segment of the market.”
|In INR Crs.||Q2FY22||Q2FY21|
|Revenue from Operations||302.6||288.4|
|EBIDTA before CSR & ESOP||93.2||94.9|
|Reported Profit After Tax||58.4||60.5|
|Reported PAT Margin (%)||19.3%||21.0%|